Summary Haemolysis and frank anaemia from dapsone therapy of leprosy has been long recognized. However, the frequency and severity of this side-effect have not been well documented. We report herein a retrospective analysis of the effect of daily dapsone (generally 100 mg/day) on the haemoglobin concentration of 100 . leprosy patients undergoing initial chemotherapy. The average haemoglobin was fo und to fall significantly by almost 2 g/dl, from 14·25 ± 1·27 g/dl to a nadir of 12·31 ± 1·61 (P < 0·00 I). Eighty-three percent of patients had a fa ll of haemoglo bin concentration of I g/dl or more, while in 16% of patients the haemoglobin fe ll � 3 g/dl. Increasing age was fo und associated with an increased magnitude of dapsone-related haemolysis (P � 0'004). Decreasing the daily dose of dapsone was associated with an increased haemoglobin concentration (P < 0·00 1 %). We have concluded that dapsone commonly results in not only haemolysis but a significant decrease in haemoglobin concentration. This may have serious clinical implica tions, especially in endemic areas, where, owing to nutrition, malaria, and intestinal parasitism, the haemoglobin concentration is already compromised.
The records of all new patients seen at the Regional Hansen's Disease Program in San Francisco between 1983 and 1988 were reviewed, and the first 100 patients who did not have excluding criteria were selected to be considered in the analyses. Patients were excluded from the study if they presented with significant anaemia before receiving dapsone or if they were already taking dapsone prior to their first clinical visit. Patients with inadequate fo llow-up were also not considered in this analysis. Patients weighing less than 45· 5 kg generally received 50 mg dapsone per day and those weighing 45· 5 kg or more received 100 mg per day on their initial visit. A complete blood count (eBe) and general chemistry panel were obtained on every patient prior to the administration of dapsone and in most cases (96/ 1 00) a G6PD level was also determined. G6PD levels were determined by measurement of the rate of production ofa product of its catalytic activity, NADPH, at its peak ultraviolet absorbance, 340 nm (normal values being 8-1 8 U/g hgb, mean ± 2 sdY Patients were seen in fo llow-up generally within one month, and thereafter at intervals between one and six months. eBe and chemistry panels were usually obtained at each visit. Those patients showing significant drops in their haemoglobin/haematocrit values often had reticulocyte counts and haptoglobin levels checked, and the dapsone dose was frequently reduced. Significant haemoglobin decreases occurring during Type II erythema nodosum leprosum (ENL) reactions or at times of intercurrent disease contributing to anaemia were not included in the analyses.
Of the one hundred patients analysed, sixty-three were male and thirty-seven were female. Their mean age was 37-4 years, with a range of 12 to 79 years. Twenty-five of these patients had lepromatous leprosy (LL), twenty had borderline lepromatous disease (BL), and fifty-four had borderline tuberculoid disease (BT). A breakdown by ethnicity revealed 37 Filipinos, 32 Southeast Asians, 18 Mexicans, 4 Indians or Pakistanis, 5 Pacific Islanders, I African, I Palestinian, and I of mixed ethnic background among the evaluated patients.
Statistical analysis was done mostly by the paired t test. The relationship of fa ll in haemoglobin and age was analysed by standard tests.6,7
Results
Of the 96 patients who had G6PD levels measured, 94 had normal levels and in two it was decreased. In one of the patients, a 27-year-old Filipino male, with a low G6PD level (0·4 U/g hgb) there was a drop in haemoglobin concentration from 15·6 g/dl to 7·2 g/dl six days after initiation of dapsone at 100 mg/day. This was the most marked decrease in haemoglobin seen in the 100 patients analysed for this study. The other patient, a 36-year old Vietnamese male, with a low G6PD level (0·8 U/g hgb) had a 2·9 g/dl drop in haemoglobin two weeks after initiating dapsone at 100 mg/day. Both had their dapsone stopped, whereafter their haemoglobin concentrations rose back to pretreatment levels.
For assessment of haemoglobin fa ll in general, the data was analysed in two different manners. In the first analysis haemoglobin nadir was used and considered to be significant if the fa ll between pretreatment levels and nadir was � I g/dl. The time between start of dapsone and nadir haemoglobin was then calculated. In the second analysis, to control * Baseline haemoglobin minus nadir haemoglobin.
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Age of patient better for selection bias, an arbitrary time interval of one month was chosen and if data at this time was not available the results from the nearest visit were used. When assessing haemoglobin nadir (see Table I and Figures I and 2 ), we found that the mean haemoglobin concentration for all patients fe ll from 14·25 ± 1·27 g/dl to 12· 31 ± 1·61 (P < 0,001). Eighty-three percent had a fa ll in haemoglobin concentration of I g/dl or more. Of these, 31 % had a haemoglobin fa ll between 1·0 and 1·9, 36% between 2·0 and 2'9, and 16% fe ll more than 3 g/dl. Analysis of the fa ll in haemoglobin nadir at intervals of 0·5 g/dl haemoglobin for the entire population studied demonstrates that the distribution of that fa ll appears unimodel (see Figures 1 & 2) . The average time to haemoglobin nadir was 16·8 ± 27·4 weeks or approximately four months. (A few patients had nadir haemoglobins at one-to-two years after starting dapsone, resulting in the large standard deviation observed.) While a greater percentage of fe males (87% us 80% male) had significant (� I g/dl) decreases in haemoglobin, a higher percentage of men (2 1 % us 8 % fe male) had more marked (�3 g/dl) haemoglobin fa lls. Increasing age was found associated with an increase in dapsone haemolysis (Pearson correlation coefficient (r) 0'287, P=0'004 and Kendall correlation coefficient 0'235, P=0·008).
When confining the analysis of haemoglobin drop essentially to the first month or so (mean 4·6 weeks ± 2-4), 72% of patients had significant drops of I g/dl or more. Of the abnormalities, 33% dropped between 1 and 1·9 g/dl, 29% between 2·0 and 2·9 g/dl, and 10% had decreases of 3 g/dl or more. Again, a higher percentage of men (13% us 5%) had the most marked haemoglobin declines. The overall mean haemoglobin concentration fe ll from 14·28 ± 1·64 g/dl to 12·66 ± 1·66 g/dl (P < 0,001).
Nineteen patients had haptoglobin levels measured during the time period investi gated. Of these, 12 (63%) had levels < 50 mg/dl, 3 (16%) were in the 50-100 mg/dl range, and 4 (2 1 %) had normal levels. While low levels were fe lt to indicate ongoing haemolysis, haptoglobin levels did not always correlate well with the degree of haemoglobin drop. Five of the patients with normal or only mild declines in haptoglobin had haemoglobin drops of 2 g/dl or greater, while 4 of the patients with haptoglobins of < 50 mg/dl had haemoglobin drops of < 2 g/dl.
Twenty patients also had reticulocyte counts measured, and ' they were found to be elevated (> 1·5%) in 17 (85%) of them. While, in general, there was no good correlation between the degree of reticulocytosis and the drop in haemoglobin, the patient with the greatest reticulocyte response (2 1 %) was the one with G6PD deficiency and the most dramatic fa ll in haemoglobin.
Among the 100 patients studied, 40 were described as having poikilocytosis or anisocytosis on blood smear after the initiation of dapsone. Elevations in total bilirubin and LDH were seen in 25% and 27% of patients respectively although the abnormalities were usually mild.
In alterations in dapsone dose would have on subsequent haemoglobin levels. The one month (or subsequent visit) haemoglobin level was used as the initial reference point. If no change in dapsone dosage was made, all subsequent haemoglobin levels on fo llow-up visits were averaged and compared to the one-month level to see whether there had been any recovery or overall fu rther decline. When there was a lowering or discontinuation of dapsone, all haemoglobin levels greater than one month after the change were averaged and again compared to the one-month value. (Haemoglobin levels were considered to have returned to normal if they were < 1 gm % lower than pretreatment levels.) As can be seen in Table 2 , on average there was some increase in haemoglobin levels even in patients who did not have their dapsone dose changed (P = 0'002), while patients who had their dapsone reduced by 50% had more marked recovery (P < 0 ,00 1). This recovery was greatest in patients who had the largest initial drop in haemoglobin and was significantly enhanced by lowering the dapsone dose. Among those patients who subsequently stopped taking dapsone, all returned to pretreatment haemoglobin levels ± 1·0 g/dl, except one patient, who exceeded his pretreatment haemoglobin by 1·5 g/dl (P < O·OOI). Figure 3 shows some representative curves for haemoglobin levels in patients who either had their dapsone continued at the initial dose, redt!ced by half, or discontinued.
Discussion
Some of the early studies of dapsone-induced haemolysis and anaemia suggested that clinically significant haemolysis occurred only at relatively high doses, larger than those normally used to treat leprosy, and that even findings of subclinical haemolysis varied considerably. DeGowin et al.3 studied 10 normal and 5 G6PD-deficient volunteers, to whom they administered between 25 and 300 mg dapsone per day, and subsequently assessed their red cell survival using 51 Cr-Iabelled erythrocytes. They concluded that no or only slight haemolysis occurred in normals taking 100 mg or less per day and in G6PD deficient subjects on 50 mg or less. Furthermore, decreases in haematocrit greater than those due to random variation were only fo und in three normals on 300 mg per day and in two G6PD-deficient subjects either on 200 mg/day or 100 mg with intercurrent infection. Similarly, Pengelly8 reported that of fo ur patients with dermatitis herpetiformis and one normal subject given between 50 and 150 mg of dapsone daily, none developed significant anaemia. However, all were fo und to have reduced RBC survival. In a larger study,2 43 patients with dermatitis herpetiformis on 50�300 mg dapsone/day were fo llowed. Red cell survival was measured in 10 patients and fo und to be reduced in all. Increasing dapsone to 150 mg or more per day invariably caused a fa ll in haemoglobin and most patients receiving 50 mg or more per day had a persistent reticulocytosis. In contrast one study 9 shows results similar to those reported herein; they fo und that 40 of 51 leprosy patients on 50� 100 mg of dapsone per day had a drop in haemoglobin of 1 g/dl or more, while 17 of them had evidence of haemolysis suggested by elevations in the reticulocyte count and indirect serum bilirubin. Our study exemplifies some of the problems of many retrospective analyses. Not all patients were checked at the same intervals or for the same length of time and not all had corroborative tests. Furthermore, no consistent documentation of missed medication doses or intercurrent infection, which might affect haemoglobin levels, was routinely made. However, with attempts to control for this, the study appears to demonstrate that significant fa lls in haemoglobin occur in a high percentage (83% or 72%, according to the analytic method used) of patients on doses of dapsone previously fe lt to cause little clinically significant anaemia.
In this present study, while only a small number of patients had haptoglobin or reticulocyte counts measured, a high percentage (79% and 85% respectively) of those who did had abnormal levels, re-emphasizing haemolysis as the probable cause for the haemoglobin decline seen with dapsone administration. G6PD deficiency has been considered a major risk factor for dapsone-caused haemolysis.1 0 Certainly, one of our patients with G6PD deficiency had a dramatic (8-4 g/dl) haemoglobin fall injust six days. The only other patient with G6PD deficiency had a more modest (2·9 g/dl) fa ll in haemoglobin, while four male patients with no demonstrable G6PD deficiency (G6PD values: 10,4, 11, 3, 12,5, and 14·7 U/g Hgb) had fa lls in haemoglobin greater than 4 g/dl within the first month, indicating that other factors probably contribute to the risk of haemolysis (anaemia) with dapsone.
Additionally, the greater recovery of haemoglobin levels with progressively decreas ing doses of dapsone points out the dose dependency for haemolysis by dapsone. It also appears, however, that if patients are maintained on dapsone at the original dose, there is some degree of bone marrow compensation, so that the final haemoglobin levels are somewhat higher than the initial drop. Drops in haemoglobin much later during treatment might be explained by intercurrent infections or mild undocumented lepra reactions which might nevertheless suppress the bone marrow's ability to compensate the ongoing haemolysis.
In summary, 100 patients fr om the San Francisco Hansen's Disease Program were retrospectively evaluated for the effect of dapsone on haemoglobin levels. It was fo und that a fa irly high percentage (72-83%) of patients treated with dapsone at 100 mg per day or less had fa lls in their haemoglobin concentrations of I g/dl or more. While some compensation and reversal of this drop was evident if patients continued on dapsone, the anaemia was fo und to be both dose-and age-related, and recovery was more marked if the dose of dapsone was reduced. One patient with G6PD deficiency had a dramatic (8·4 g/dl) fa ll in his haemoglobin level necessitating not only in the drug being discontinued but also being given a red cell transfusion.
